Braveheart Bio BRVE
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: +$2.82M (10 inflow days, 10 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 73.7% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 1.20% to 5.72% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Charles Schwab Investment Management | Mutual Fund | 2026/Q3 | +129,720 | 0.2% |
| FMR | Mutual Fund | 2026/Q3 | +7,585,769 | 9.3% |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Public Company | 2026/Q3 | +7,420,091 | 9.1% |
| Capital Research | Mutual Fund | 2026/Q3 | +2,334,097 | 2.9% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +1,131,988 | 1.4% |
| BlackRock | Mutual Fund | 2026/Q3 | +1,007,129 | 1.2% |
| MFS Investment Management | Mutual Fund | 2026/Q3 | +465,251 | 0.6% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +288,798 | 0.4% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +229,072 | 0.3% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +182,118 | 0.2% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +9,111 | 0.0% |
| OrbiMed Advisors LLC | VC/PE Fund | 2026/Q3 | +12,175,159 | 14.9% |
| BlackRock | Mutual Fund | 2026/Q3 | +132,958 | 0.2% |
| Strategic Advisers LLC | Mutual Fund | 2026/Q3 | +82,374 | 0.1% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +52,571 | 0.1% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 6 Aug 2026 | OrbiMed Advisors LLC | Private Acquisition | +1,940,000 | $18.00 | 12,175,159 | |
| 6 Aug 2026 | OrbiMed Advisors LLC | Derivative Exercise and Retained | +9,132,420 | – | 12,175,159 | |
| 6 Aug 2026 | David Lubner | Independent Director | Private Acquisition | +55,555 | $18.00 | 55,555 |
| 6 Aug 2026 | Christopher Viehbacher | Independent Chairperson | Private Acquisition | +83,333 | $18.00 | 609,519 |
| 6 Aug 2026 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Derivative Exercise and Retained | +7,420,091 | – | 7,420,091 | |
| 6 Aug 2026 | Forbion Capital Partners B.V. | Private Acquisition | +3,600,000 | $18.00 | 21,826,024 | |
| 6 Aug 2026 | Forbion Capital Partners B.V. | Derivative Exercise and Retained | +17,123,287 | – | 21,826,024 | |
| 6 Aug 2026 | Andreessen Horowitz LLC | Private Acquisition | +1,100,000 | $18.00 | 10,232,420 | |
| 6 Aug 2026 | Andreessen Horowitz LLC | Derivative Exercise and Retained | +9,132,420 | – | 10,232,420 | |
| 6 Aug 2026 | Andreessen Horowitz LLC | Initial Statement of Beneficial | +0 | – | 10,232,420 | |
| 6 Aug 2026 | David Malek | Director | Private Acquisition | +4,166 | $18.00 | 1,013,297 |
| 6 Aug 2026 | James Rickey | Chief Financial Officer | Private Acquisition | +27,777 | $18.00 | 703,575 |
| 6 Aug 2026 | Michele Anderson | Chief Development Officer | Private Acquisition | +1,111 | $18.00 | 332,161 |
| 6 Aug 2026 | Travis Murdoch | Chief Executive Officer | Private Acquisition | +83,333 | $18.00 | 8,333,637 |
| 4 Aug 2026 | OrbiMed Advisors LLC | Initial Statement of Beneficial | +0 | – | 1,102,739 | |
| 4 Aug 2026 | David Lubner | Independent Director | Other Derivative Acquisition | +60,000 | $18.00 | 60,000 |
| 4 Aug 2026 | Christopher Viehbacher | Independent Chairperson | Other Derivative Acquisition | +30,000 | $18.00 | 30,000 |
| 4 Aug 2026 | Christopher Viehbacher | Independent Chairperson | Initial Statement of Beneficial | +0 | – | 676,524 |
| 4 Aug 2026 | Erez Chimovits | Independent Director | Other Derivative Acquisition | +30,000 | $18.00 | 30,000 |
| 4 Aug 2026 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Initial Statement of Beneficial | +0 | – | 7,420,091 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 5,153,595 | 5.7% | 19.6 |
| 15 Oct 2026 | 4,905,289 | 5.4% | 11.8 |
| 30 Sep 2026 | 4,128,974 | 4.6% | 5.1 |
| 15 Sep 2026 | 2,461,086 | 2.7% | 7.5 |
| 31 Aug 2026 | 1,397,189 | 2.0% | 5.6 |
| 14 Aug 2026 | 847,773 | 1.2% | 1.3 |
No comments yet — be the first to weigh in on BRVE.
Sign in to join the discussion.